Clinical Study
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain
Table 2
Summary of adverse events.
| | 5-ALA-SFC
| Placebo
|
| Subjects reporting at least one event | 16 (45.7%) | 5 (27.8%) | Subjects reporting at least one related event | 7 (20%) | 3 (16.7%) | Subjects reporting at least one severe event | 0 | 0 | Subjects reporting at least one event leading to study discontinuation | 6 (17.1%) | 1 (5.6%) |
|
|
= 0.206.
|